Lung cancer remains the leading cause of cancer-related deaths in the United States, but advances in early detection and treatment are improving the outlook for patients. Over the past two decades, five-year survival rates have nearly doubled, rising from 15% to 27% – progress driven in large part by clinical research. This Lung Cancer Awareness…
NCI-supported cooperative group highlights its eight ongoing clinical trials focused on improving cancer detection, treatment, and survivorship Every November, millions worldwide grow mustaches and join Movember, a global movement launched in 2003 to spark conversations about men’s health, including prostate cancer, testicular cancer, and mental health. The initiative encourages men to challenge stigmas, prioritize their…
The media relations efforts from Alliance staff and researchers are designed to alert the public about the vital work happening across our network. When we share stories about clinical trial results, scientific milestones, and investigator achievements, we are showcasing the real-world progress you help make possible. See where the Alliance was mentioned in October 2026…
Published in Journal of Clinical Oncology, findings provide evidence that shortening radiation schedule does not sacrifice treatment success or impair reconstruction efforts Results of a national clinical trial led by the Alliance for Clinical Trials in Oncology in conjunction with NRG Oncology and the Canadian Cancer Trials Group show that a shorter, three-week radiation schedule…
Research progress in breast cancer is saving lives, improving treatments, and offering hope to millions of people. Yet breast cancer remains a significant public health challenge, underscoring the continued need for research, earlier detection, and more effective treatment options. Breast cancer is the most common cancer in American women, after skin cancers, accounting for about…
The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has approved the immunotherapy drug atezolizumab (Tecentriq®) in combination with fluoropyrimidine and oxaliplatin chemotherapy, for the adjuvant treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The approval is based on…
A Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with SignateraTM MRD-Guided CDK4/6 Inhibitor Therapy in ER-Positive/HER2-Negative Early-Stage Breast Cancer Trial will utilize Natera’s ultrasensitive MRD test, Signatera Genome with Phased and Structural Variants, paired with giredestrant monotherapy, Genentech’s oral SERD, with the objective to spare patients from unnecessary CDK4/6…
The media relations efforts from Alliance staff and researchers are designed to alert the public about the vital work happening across our network. When we share stories about clinical trial results, scientific milestones, or investigator achievements, we are showcasing the real-world progress you help make possible. See where the Alliance was mentioned September 2026 in…
Presented at ASTRO plenary session, Phase III trial results show three to five radiation treatments improved control at the surgical site compared with a single treatment Delivering focused radiation therapy over three to five sessions after surgery for a large brain metastasis reduced the risk of cancer returning at the surgical site compared with delivering…
Public October 1 event will feature key treatment advances impacting people with breast, lung and prostate cancers New research is changing what we know about breast, lung, and prostate cancers. On Thursday, October 1, the Alliance for Clinical Trials in Oncology will host a public webinar highlighting key findings from Alliance and Alliance Foundation Trials…